Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results

      - Full-Year 2019 GAAP Net Revenues of $16.1 Billion; Q4 2019 GAAP Net Revenues of $4.4 Billion -

      - Full-Year 2019 GAAP Loss Per Share of $16.02; Non-GAAP Performance Net Income Per Share of $17.64 -

      - Q4 2019 GAAP Loss Per Share of $0.97; Non-GAAP Performance Net Income Per Share of $5.22 -

      - Q4 2019 GAAP Operating Loss of $276.6 Million; Non-GAAP Operating Income of $2.08 Billion -

      - Full-Year and Q4 2019 GAAP Net Revenue Driven by Growth in Top Promoted Products Including VRAYLAR®, BOTOX®, JUVÉDERM® Collection, OZURDEX® and Lo LOESTRIN®; Global Facial Aesthetics Rose 9.5% in FY 2019 and 8.2% in Q4 2019 (Excluding Exchange) -

      - Continues to Advance R&D Pipeline on Key Programs Including FDA Approval of UBRELVY™ (Ubrogepant) for Migraine; Bimatoprost SR for Glaucoma NDA and Abicipar for Wet Age-Related Macular Degeneration BLA Under FDA Review -

      Allergan plc logo

      News provided by

      Allergan plc

      Feb 10, 2020, 07:00 ET

      Share this article

      Share this article


      DUBLIN, Feb. 10, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its full-year and fourth quarter 2019 financial results including full-year 2019 GAAP net revenues of $16.1 billion, a 1.9 percent increase from 2018. Fourth quarter 2019 GAAP net revenues were $4.35 billion, a 6.6 percent increase from the prior year quarter.

      FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

       (unaudited; $ in millions, except per share amounts)


      Q4 '19



      Q4 '18



      Q4 '19 v Q4
      '18



      Year Ended December 31, 2019



      Year Ended December 31, 2018



      2019 v 2018


      Total Net Revenues


      $

      4,351.0



      $

      4,079.7




      6.6

      %


      $

      16,088.9



      $

      15,787.4




      1.9

      %


























      Operating (Loss)


      $

      (276.6)



      $

      (5,384.1)




      94.9

      %


      $

      (4,445.3)



      $

      (6,247.6)




      28.8

      %

      Diluted EPS


      $

      (0.97)



      $

      (12.83)




      92.4

      %


      $

      (16.02)



      $

      (15.26)




      (5.0)

      %

      SG&A Expense


      $

      1,639.6



      $

      1,193.6




      37.4

      %


      $

      5,943.5



      $

      4,521.8




      31.4

      %

      R&D Expense


      $

      452.5



      $

      678.1




      (33.3)

      %


      $

      1,812.0



      $

      2,266.2




      (20.0)

      %

      Tax Rate



      24.8

      %



      23.2

      %



      1.6

      %



      (2.9)

      %



      25.8

      %



      (28.7)

      %


























      Non-GAAP Net Revenues


      $

      4,351.0



      $

      4,079.7




      6.6

      %


      $

      16,063.9



      $

      15,762.4




      1.9

      %

      Non-GAAP Operating Income


      $

      2,079.3



      $

      1,917.8




      8.4

      %


      $

      7,314.5



      $

      7,555.8




      (3.2)

      %

      Non-GAAP Performance Net Income Per Share


      $

      5.22



      $

      4.29




      21.7

      %


      $

      17.64



      $

      16.69




      5.7

      %

      Non-GAAP Adjusted EBITDA


      $

      2,205.8



      $

      1,990.5




      10.8

      %


      $

      7,760.1



      $

      7,954.1




      (2.4)

      %

      Non-GAAP SG&A Expense


      $

      1,162.2



      $

      1,140.4




      1.9

      %


      $

      4,600.6



      $

      4,354.9




      5.6

      %

      Non-GAAP R&D Expense


      $

      414.8



      $

      436.1




      (4.9)

      %


      $

      1,708.6



      $

      1,574.5




      8.5

      %

      Non-GAAP Tax Rate



      10.3

      %



      14.3

      %



      (4.0)

      %



      11.7

      %



      14.2

      %



      (2.5)

      %


























      Executive Commentary

      "I am proud of Allergan's colleagues who achieved many important milestones in 2019 that will make a difference to patients for years to come. They achieved FDA approval of UBRELVY™, a first-in-class oral treatment for migraine; two new approvals for BOTOX® for pediatric spasticity; approval for VRAYLAR® for bipolar depression; and filings for two new eye care drugs - Bimatoprost SR for glaucoma and Abicipar for Age-related Macular Degeneration," said Brent Saunders, Chairman and CEO of Allergan. "Our colleagues also grew our core business1 by 7.1 percent in 2019 and by 11.0 percent in the fourth quarter (excluding exchange), creating strong momentum for 2020 and our proposed combination with AbbVie."

      Full-Year 2019 Financial Results

      GAAP operating loss in 2019 was $4.45 billion compared with $6.25 billion in 2018. Non-GAAP operating income, which excludes the impact of impairments, amortization and other items, was $7.31 billion in 2019 compared to $7.56 billion in 2018. GAAP cash flow from operations for the full year of 2019 totaled $7.24 billion. Cash flow from operations for the full year of 2019 includes a one-time $1.6 billion refund of taxes previously paid on capital gains. The tax refund was accrued in a prior period and the cash was received in the third quarter of 2019.

      Fourth Quarter 2019 Financial Results

      GAAP operating loss in the fourth quarter of 2019 was $276.6 million. Non-GAAP operating income in the fourth quarter of 2019 was $2.08 billion, an increase of 8.4 percent versus the prior year quarter. GAAP cash flow from operations for the fourth quarter of 2019 totaled $1.67 billion.

      Operating Expenses

      Total GAAP Selling, General and Administrative (SG&A) Expense was $1.64 billion for the fourth quarter of 2019, compared to $1.19 billion in the prior year quarter. Total non-GAAP SG&A expense was $1.16 billion for the fourth quarter of 2019, an increase of 1.9 percent from the prior year quarter, primarily related to an increase in spending to support key products and new product launches. GAAP R&D investment for the fourth quarter of 2019 was $452.5 million, compared to $678.1 million in the fourth quarter of 2018. Non-GAAP R&D investment for the fourth quarter of 2019 was $414.8 million, a decrease of 4.9 percent compared to the prior year quarter.

      Amortization, Tax and Capitalization

      Amortization expense for the fourth quarter of 2019 was $1.52 billion, compared to $1.57 billion in the fourth quarter of 2018. The Company's GAAP tax rate was 24.8 percent in the fourth quarter of 2019. The Company's non-GAAP adjusted tax rate was 10.3 percent in the fourth quarter of 2019. As of December 31, 2019, Allergan had cash and marketable securities of $5.91 billion and outstanding indebtedness of $22.6 billion.

      Operating Charges and Impairments

      Allergan recorded a pre-tax charge of $302.5 million in the three months ended December 31, 2019 related to settlements reached in principle by subsidiaries Warner Chilcott and Watson with direct and indirect purchasers of LOESTRIN® 24 Fe and MINASTRIN® 24 Fe, resolving class action litigations pending in the U.S. District Court for the District of Rhode Island. Additionally, Allergan recorded a pre-tax charge of $78.8 million in the three months ended December 31, 2019 related to settlements reached in principle by its Allergan Inc. subsidiary with a putative plaintiff class of direct purchasers of RESTASIS®, as well as a group of pharmaceutical retailers, in the previously disclosed direct purchaser class action antitrust litigation pending in the U.S. District Court for the Eastern District of New York. Also in the fourth quarter of 2019, Allergan recorded a $314.0 million GAAP intangible asset impairment related to CARAFATE® due to the entry of a generic competitor. The Company excludes operating charges, asset sales and impairments, net and in-process research and development impairments from its Non-GAAP performance net income attributable to shareholders as well as Adjusted EBITDA and Non-GAAP Operating Income.

      1 Core business = Promoted Brands & Brands with Ongoing Exclusivity + Other Product Revenues & Other Revenues (See Table 12)

      FOURTH QUARTER 2019 BUSINESS SEGMENT RESULTS

      U.S. Specialized Therapeutics

      U.S. Specialized Therapeutics net revenues were $1.82 billion in the fourth quarter of 2019, an increase of 0.7 percent versus the prior year quarter. Demand growth in BOTOX® Therapeutic, BOTOX® Cosmetic, ALLODERM® and JUVÉDERM® Collection was offset by a decline in sales of CoolSculpting® and lower RESTASIS® revenues compared to the prior year quarter. Segment gross margin for the fourth quarter of 2019 was 91.4 percent. Segment contribution for the fourth quarter of 2019 was $1.24 billion.

      Medical Aesthetics

      • Facial Aesthetics
        • BOTOX® Cosmetic net revenues in the fourth quarter of 2019 were $271.8 million, an increase of 5.3 percent from the prior year quarter. For full-year 2019, BOTOX® Cosmetic net revenues were $991.3 million, an increase of 9.3 percent from 2018.
        • JUVÉDERM® Collection (defined as JUVÉDERM®, VOLUMA® and other fillers) net revenues in the fourth quarter of 2019 were $166.4 million, an increase of 5.1 percent versus the prior year quarter. For full-year 2019, JUVÉDERM® Collection net revenues were $587.5 million, an increase of 7.2 percent from 2018.
      • Regenerative Medicine
        • ALLODERM® net revenues in the fourth quarter of 2019 were $104.7 million, an increase of 10.3 percent versus the prior year quarter.
      • Body Contouring
        • CoolSculpting® net revenues (including both CoolSculpting® Systems/Applicators and Consumables) in the fourth quarter of 2019 were $53.3 million, a decrease of 34.4 percent from the prior year quarter.
        • CoolTone™ received regulatory clearance in the U.S. in 2019 and full launch began in January 2020.

      Neurosciences & Urology

      • BOTOX® Therapeutic net revenues in the fourth quarter of 2019 were $463.0 million, an increase of 6.9 percent versus the prior year quarter.

      Eye Care

      • RESTASIS® net revenues in the fourth quarter of 2019 were $309.0 million, a decrease of 4.9 percent versus the prior year quarter.
      • ALPHAGAN®/COMBIGAN® net revenues in the fourth quarter of 2019 were $94.5 million, a decrease of 3.3 percent versus the prior year quarter.
      • OZURDEX® net revenues in the fourth quarter of 2019 were $31.6 million, an increase of 7.8 percent versus the prior year quarter.

      U.S. General Medicine

      U.S. General Medicine net revenues in the fourth quarter of 2019 were $1.61 billion, an increase of 15.2 percent versus the prior year quarter. Demand growth in VRAYLAR®, LINZESS®, VIIBRYD® and Lo LOESTRIN® was partially offset by lower revenues from products that lost exclusivity. Segment gross margin for the fourth quarter of 2019 was 82.1 percent. Segment contribution for the fourth quarter of 2019 was $1.03 billion.

      Central Nervous System

      • VRAYLAR® net revenues were $283.1 million in the fourth quarter of 2019, an increase of 88.1 percent from the prior year quarter. For full-year 2019, VRAYLAR® net revenues were $857.5 million, an increase of 76.0 percent from 2018.
      • VIIBRYD®/FETZIMA® net revenues in the fourth quarter of 2019 were $114.2 million, an increase of 19.6 percent from the prior year quarter.

      Gastrointestinal, Women's Health & Diversified Brands

      • LINZESS® net revenues in the fourth quarter of 2019 were $231.2 million, an increase of 12.7 percent versus the prior year quarter.
      • Lo LOESTRIN® net revenues in the fourth quarter of 2019 were $156.2 million, an increase of 8.6 percent versus the prior year quarter.
      • BYSTOLIC®/BYVALSON® net revenues in the fourth quarter of 2019 were $169.6 million, an increase of 11.8 percent from the prior year quarter.

      International

      International net revenues in the fourth quarter of 2019 were $917.7 million, an increase of 8.1 percent versus the prior year quarter excluding foreign exchange impact, partly due to growth in Facial Aesthetics, BOTOX® Therapeutic and OZURDEX®. Segment gross margin for the fourth quarter of 2019 was 83.8 percent. Segment contribution was $515.8 million.

      Facial Aesthetics

      • BOTOX® Cosmetic net revenues in the fourth quarter of 2019 were $182.9 million, an increase of 19.8 percent versus the prior year quarter excluding foreign exchange impact. For full-year 2019, BOTOX® Cosmetic net revenues were $671.7 million, an increase of 11.2 percent from 2018 excluding foreign exchange impact.
      • JUVÉDERM® Collection net revenues in the fourth quarter of 2019 were $180.9 million, an increase of 5.7 percent versus the prior year quarter excluding foreign exchange impact. For full-year 2019, JUVÉDERM® Collection net revenues were $656.1 million, an increase of 12.1 percent from 2018 excluding foreign exchange impact.

      Eye Care

      • LUMIGAN®/GANFORT® net revenues in the fourth quarter of 2019 were $95.6 million, an increase of 1.4 percent versus the prior year quarter excluding foreign exchange impact.
      • OZURDEX® net revenues in the fourth quarter of 2019 were $66.7 million, an increase of 132.8 percent versus the prior year quarter excluding foreign exchange impact. OZURDEX® growth was primarily related to a return to full stock in 2019 following a 2018 recall of OZURDEX® in certain international markets.

      Botox® Therapeutic

      • BOTOX® Therapeutic net revenues in the fourth quarter of 2019 were $102.5 million, an increase of 8.9 percent versus the prior year quarter excluding foreign exchange impact.

      PIPELINE UPDATE

      Allergan R&D continues to advance its pipeline. During the fourth quarter of 2019, the Company's key clinical developments included:

      • Allergan received approval from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for UBRELVY™ (ubrogepant) for the acute treatment of migraine with or without aura in adults. UBRELVY™ is a first-in-class oral CGRP receptor antagonist (gepant) for the treatment of migraine attacks once they start. Launch began in January 2020.
      • Allergan announced the FDA has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for ATM-AVI (aztreonam and avibactam) for the treatment of antibiotic-resistant gram-negative infections including complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). ATM-AVI is an investigational, fixed-dose, intravenous combination antibiotic being developed jointly with Pfizer.
      • The FDA approved Allergan's supplemental Biologics License Application (sBLA) to expand the BOTOX® (onabotulinumtoxinA) label for the treatment of pediatric patients ages two years and older with lower limb spasticity, excluding spasticity caused by cerebral palsy. This marks the 14th approved indication for BOTOX® and BOTOX® Cosmetic combined in the U.S., and the 11th BOTOX® therapeutic indication. The FDA approved BOTOX® (onabotulinumtoxinA) for pediatric upper limb spasticity in the second quarter of 2019.

      In addition to fourth quarter 2019 pipeline developments listed above, Allergan expects two additional significant launches in the next twelve months:

      • FDA action is expected in the first half of 2020 on Allergan's NDA for Bimatoprost Sustained-Release, a biodegradable implant for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch is expected to follow in the first half of 2020.
      • The FDA is currently reviewing a Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin® therapy, in patients with neovascular (wet) age-related macular degeneration (nAMD). The FDA is expected to take action on the BLA in mid-2020, with launch expected to follow. The European Medicines Agency (EMA) is also reviewing a Marketing Authorisation Application (MAA) for Abicipar in patients with nAMD. A decision from the European Commission is expected in the second half of 2020.

      UPDATE ON PROPOSED ABBVIE TRANSACTION

      On January 10, 2020, AbbVie and Allergan received conditional approval from the European Commission for AbbVie's proposed acquisition of Allergan, subject to the approved divestiture of brazikumab (IL-23 inhibitor) and other conditions.

      On January 27, 2020, Allergan announced that it entered into definitive agreements to divest brazikumab and ZENPEP® (pancrelipase) in conjunction with the ongoing regulatory approval process for the proposed transaction.

      AstraZeneca will acquire brazikumab, currently in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

      Nestle will acquire and take full operational ownership of ZENPEP® upon closing the transaction with customary transition support from Allergan. ZENPEP® is a treatment, which is available in the United States, for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestle also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

      The closings of the divestitures of brazikumab and ZENPEP® are contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, closing of AbbVie's pending acquisition of Allergan and the satisfaction of other customary closing conditions.

      Allergan expects the close of the pending AbbVie transaction around the end of the first quarter 2020, subject to receipt of required regulatory approvals and other closing conditions.

      Due to the pending transaction, Allergan is not hosting a conference call to discuss its fourth quarter and full-year 2019 results.

       

      Allergan Contacts:


      Investors:


      Manisha Narasimhan, PhD

      (862) 261-7162



      Media:


      Lisa Brown

      (862) 261-7320

       

      About Allergan plc

      Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

      With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

      For more information, visit Allergan's website at www.Allergan.com.

      Forward-Looking Statement

      Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected debt reduction, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; risks related to the proposed transaction between AbbVie and Allergan, such as, but not limited to, failure to complete the possible transaction, failure to realize the expected benefits of the possible transaction, and general economic and business conditions affecting the combined company following the consummation of the possible transaction;and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

      Statements Required by the Irish Takeover Rules

      No statement in this press release is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Allergan. No statement in this press release constitutes an asset valuation.

      The directors of Allergan accept responsibility for the information contained in this press release. To the best of the knowledge and belief of the directors of Allergan (who have taken all reasonable care to ensure that such is the case), the information contained in this press release is in accordance with the facts and does not omit anything likely to affect the import of such information.

      Any holder of 1% or more of any class of relevant securities of Allergan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

       

      The following presents Allergan plc's statement of operations for the three and twelve months ended December 31, 2019 and 2018:

      Table 1




      ALLERGAN PLC

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Unaudited; in millions, except per share amounts)






















      Three Months Ended



      Year Ended






      December 31,



      December 31,






      2019



      2018



      2019



      2018




      Net revenues


      $

      4,351.0



      $

      4,079.7



      $

      16,088.9



      $

      15,787.4























      Operating expenses:





















      Cost of sales (excludes amortization and impairment of acquired
      intangibles including product rights)



      704.0




      590.0




      2,493.1




      2,191.4




      Research and development



      452.5




      678.1




      1,812.0




      2,266.2




      Selling, general and administrative



      1,639.6




      1,193.6




      5,943.5




      4,521.8




      Amortization



      1,517.5




      1,569.1




      5,856.6




      6,552.3




      In-process research and development impairments



      -




      6.6




      436.0




      804.6




      Goodwill and other asset impairments / sales, net



      314.0




      5,426.4




      3,993.0




      5,698.7




      Total operating expenses



      4,627.6




      9,463.8




      20,534.2




      22,035.0




      Operating (loss)



      (276.6)




      (5,384.1)




      (4,445.3)




      (6,247.6)























      Non-operating income (expense):



















      Interest income



      25.3




      11.6




      76.8




      45.2




      Interest (expense)



      (191.9)




      (210.2)




      (783.0)




      (911.2)




      Other income (expense), net



      21.2




      (9.9)




      32.8




      256.7




      Total other income (expense), net



      (145.4)




      (208.5)




      (673.4)




      (609.3)




      (Loss) before income taxes and noncontrolling interest



      (422.0)




      (5,592.6)




      (5,118.7)




      (6,856.9)




      (Benefit) / provision for income taxes



      (104.7)




      (1,296.7)




      146.4




      (1,770.7)




      Net (loss)



      (317.3)




      (4,295.9)




      (5,265.1)




      (5,086.2)




      Loss / (income) attributable to noncontrolling interest



      0.1




      (4.0)




      (5.9)




      (10.2)




      Net (loss) attributable to shareholders



      (317.2)




      (4,299.9)




      (5,271.0)




      (5,096.4)




      Dividends on preferred shares



      -




      -




      -




      46.4




      Net (loss) attributable to ordinary shareholders


      $

      (317.2)



      $

      (4,299.9)



      $

      (5,271.0)



      $

      (5,142.8)























      (Loss) per share attributable to ordinary shareholders:



















      Net (loss) per share - basic


      $

      (0.97)



      $

      (12.83)



      $

      (16.02)



      $

      (15.26)




      Net (loss) per share - diluted



      (0.97)




      (12.83)




      (16.02)




      (15.26)























      Weighted average shares outstanding:



















      Basic



      328.4




      335.1




      329.0




      337.0




      Diluted



      328.4




      335.1




      329.0




      337.0

























       

      The following table details Allergan plc's product revenue for significant promoted products globally, within the U.S., and international for the three and twelve months ended December 31, 2019 and 2018.


      Table 2


      ALLERGAN PLC


      NET REVENUES TOP GLOBAL PRODUCTS


      (Unaudited; in millions)





















































      Three Months Ended December 31, 2019



      Three Months Ended December 31, 2018



      Movement




      US Specialized Therapeutics



      US General Medicine



      International



      Corporate



      Total



      US Specialized Therapeutics



      US General Medicine



      International



      Corporate



      Total



      Total Change



      Total Change Percentage



















































      Botox®


      $

      734.8



      $

      -



      $

      285.4



      $

      -



      $

      1,020.2



      $

      691.4



      $

      -



      $

      254.5



      $

      -



      $

      945.9



      $

      74.3




      7.9

      %

      Restasis®



      309.0




      -




      18.7




      -




      327.7




      325.0




      -




      16.6




      -




      341.6




      (13.9)




      (4.1)

      %

      Juvederm® Collection



      166.4




      -




      180.9




      -




      347.3




      158.4




      -




      174.0




      -




      332.4




      14.9




      4.5

      %

      Lumigan®/Ganfort®



      81.9




      -




      95.6




      -




      177.5




      74.0




      -




      96.9




      -




      170.9




      6.6




      3.9

      %

      Linzess®/Constella®



      -




      231.2




      6.8




      -




      238.0




      -




      205.2




      6.4




      -




      211.6




      26.4




      12.5

      %

      Bystolic®/Byvalson®



      -




      169.6




      0.6




      -




      170.2




      -




      151.7




      0.4




      -




      152.1




      18.1




      11.9

      %

      Alphagan®/Combigan®



      94.5




      -




      43.1




      -




      137.6




      97.7




      -




      46.7




      -




      144.4




      (6.8)




      (4.7)

      %

      Lo Loestrin®



      -




      156.2




      -




      -




      156.2




      -




      143.8




      -




      -




      143.8




      12.4




      8.6

      %

      Breast Implants



      67.1




      -




      15.1




      -




      82.2




      68.2




      -




      10.5




      -




      78.7




      3.5




      4.4

      %

      Viibryd®/Fetzima®



      -




      114.2




      3.6




      -




      117.8




      -




      95.5




      2.3




      -




      97.8




      20.0




      20.4

      %

      Eye Drops



      61.2




      -




      59.3




      -




      120.5




      47.9




      -




      71.7




      -




      119.6




      0.9




      0.8

      %

      Asacol®/Delzicol®



      -




      8.5




      8.9




      -




      17.4




      -




      27.9




      10.7




      -




      38.6




      (21.2)




      (54.9)

      %

      Coolsculpting® Consumables



      36.4




      -




      16.6




      -




      53.0




      54.5




      -




      23.4




      -




      77.9




      (24.9)




      (32.0)

      %

      Coolsculpting® Systems & Add On
      Applicators



      16.9




      -




      8.8




      -




      25.7




      26.8




      -




      21.5




      -




      48.3




      (22.6)




      (46.8)

      %

      Ozurdex®



      31.6




      -




      66.7




      -




      98.3




      29.3




      -




      29.6




      -




      58.9




      39.4




      66.9

      %

      Carafate®/Sulcrate®



      -




      46.9




      0.9




      -




      47.8




      -




      54.1




      0.7




      -




      54.8




      (7.0)




      (12.8)

      %

      Aczone®



      2.5




      -




      -




      -




      2.5




      0.6




      -




      0.1




      -




      0.7




      1.8



      n.m.


      Zenpep®



      -




      80.8




      0.5




      -




      81.3




      -




      66.8




      0.4




      -




      67.2




      14.1




      21.0

      %

      Canasa®/Salofalk®



      -




      7.5




      4.7




      -




      12.2




      -




      38.8




      4.5




      -




      43.3




      (31.1)




      (71.8)

      %

      Vraylar®



      -




      283.1




      -




      -




      283.1




      -




      150.5




      -




      -




      150.5




      132.6




      88.1

      %

      Saphris®



      -




      36.3




      -




      -




      36.3




      -




      36.8




      -




      -




      36.8




      (0.5)




      (1.4)

      %

      Viberzi®



      -




      49.8




      0.4




      -




      50.2




      -




      48.9




      0.6




      -




      49.5




      0.7




      1.4

      %

      Teflaro®



      -




      38.1




      3.7




      -




      41.8




      -




      30.0




      -




      -




      30.0




      11.8




      39.3

      %

      Namzaric®



      -




      20.2




      -




      -




      20.2




      -




      22.6




      -




      -




      22.6




      (2.4)




      (10.6)

      %

      Rapaflo®



      2.0




      -




      2.5




      -




      4.5




      18.9




      -




      1.8




      -




      20.7




      (16.2)




      (78.3)

      %

      Skin Care



      44.6




      -




      4.2




      -




      48.8




      40.4




      -




      3.6




      -




      44.0




      4.8




      10.9

      %

      Kybella®/Belkyra®



      6.3




      -




      0.8




      -




      7.1




      7.2




      -




      1.0




      -




      8.2




      (1.1)




      (13.4)

      %

      Alloderm®



      104.7




      -




      2.0




      -




      106.7




      94.9




      -




      2.5




      -




      97.4




      9.3




      9.5

      %

      Dalvance®



      -




      26.4




      2.4




      -




      28.8




      -




      17.3




      1.0




      -




      18.3




      10.5




      57.4

      %

      Avycaz®



      -




      30.7




      -




      -




      30.7




      -




      24.6




      -




      -




      24.6




      6.1




      24.8

      %

      Liletta®



      -




      22.5




      -




      -




      22.5




      -




      14.6




      -




      -




      14.6




      7.9




      54.1

      %

      Namenda®



      -




      3.2




      -




      -




      3.2




      -




      10.7




      -




      -




      10.7




      (7.5)




      (70.1)

      %

      Armour Thyroid



      -




      57.4




      -




      -




      57.4




      -




      53.4




      -




      -




      53.4




      4.0




      7.5

      %

      Savella®



      -




      21.5




      -




      -




      21.5




      -




      23.6




      -




      -




      23.6




      (2.1)




      (8.9)

      %

      Other Products Revenues



      61.3




      206.6




      85.5




      1.4




      354.8




      73.6




      181.1




      88.8




      2.8




      346.3




      8.5




      2.5

      %

      Total Net Revenues


      $

      1,821.2



      $

      1,610.7



      $

      917.7



      $

      1.4




      4,351.0



      $

      1,808.8



      $

      1,397.9



      $

      870.2



      $

      2.8




      4,079.7



      $

      271.3




      6.6

      %





































































































      1Botox® is comprised of the following:

















































      Botox® Therapeutics



      463.0




      -




      102.5




      -




      565.5




      433.3




      -




      96.7




      -




      530.0




      35.5




      6.7

      %

      Botox® Cosmetics



      271.8




      -




      182.9




      -




      454.7




      258.1




      -




      157.8




      -




      415.9




      38.8




      9.3

      %















































































































































































































































































































































































































































































































































































































      Twelve Months Ended December 31, 2019



      Twelve Months Ended December 31, 2018



      Movement




      US Specialized Therapeutics



      US General Medicine



      International



      Corporate



      Total



      US Specialized Therapeutics



      US General Medicine



      International



      Corporate



      Total



      Total Change



      Total Change Percentage



















































      Botox®


      $

      2,730.5



      $

      -



      $

      1,060.8



      $

      -



      $

      3,791.3



      $

      2,545.8



      $

      -



      $

      1,031.6



      $

      -



      $

      3,577.4



      $

      213.9




      6.0

      %

      Restasis®



      1,138.4




      -




      50.2




      -




      1,188.6




      1,197.0




      -




      64.5




      -




      1,261.5




      (72.9)




      (5.8)

      %

      Juvederm® Collection



      587.5




      -




      656.1




      -




      1,243.6




      548.2




      -




      614.8




      -




      1,163.0




      80.6




      6.9

      %

      Lumigan®/Ganfort®



      269.2




      -




      360.8




      -




      630.0




      291.8




      -




      392.6




      -




      684.4




      (54.4)




      (7.9)

      %

      Linzess®/Constella®



      -




      803.2




      23.8




      -




      827.0




      -




      761.1




      24.1




      -




      785.2




      41.8




      5.3

      %

      Bystolic®/Byvalson®



      -




      600.6




      2.1




      -




      602.7




      -




      583.8




      2.0




      -




      585.8




      16.9




      2.9

      %

      Alphagan®/Combigan®



      360.0




      -




      162.0




      -




      522.0




      375.4




      -




      176.0




      -




      551.4




      (29.4)




      (5.3)

      %

      Lo Loestrin®



      -




      588.9




      -




      -




      588.9




      -




      527.7




      -




      -




      527.7




      61.2




      11.6

      %

      Breast Implants



      254.4




      -




      0.6




      -




      255.0




      263.0




      -




      130.1




      -




      393.1




      (138.1)




      (35.1)

      %

      Viibryd®/Fetzima®



      -




      412.1




      11.4




      -




      423.5




      -




      342.4




      7.2




      -




      349.6




      73.9




      21.1

      %

      Eye Drops



      230.4




      -




      235.8




      -




      466.2




      202.7




      -




      279.7




      -




      482.4




      (16.2)




      (3.4)

      %

      Asacol®/Delzicol®



      -




      76.7




      36.1




      -




      112.8




      -




      130.8




      45.7




      -




      176.5




      (63.7)




      (36.1)

      %

      Coolsculpting® Consumables



      185.3




      -




      76.3




      -




      261.6




      235.3




      -




      64.2




      -




      299.5




      (37.9)




      (12.7)

      %

      Coolsculpting® Systems & Add On
      Applicators



      62.8




      -




      42.4




      -




      105.2




      126.3




      -




      43.3




      -




      169.6




      (64.4)




      (38.0)

      %

      Alloderm®



      395.9




      -




      7.9




      -




      403.8




      407.3




      -




      8.0




      -




      415.3




      (11.5)




      (2.8)

      %

      Ozurdex®



      125.5




      -




      274.6




      -




      400.1




      111.0




      -




      187.7




      -




      298.7




      101.4




      33.9

      %

      Carafate®/Sulcrate®



      -




      212.5




      3.0




      -




      215.5




      -




      217.8




      2.8




      -




      220.6




      (5.1)




      (2.3)

      %

      Aczone®



      9.3




      -




      -




      -




      9.3




      55.1




      -




      0.4




      -




      55.5




      (46.2)




      (83.2)

      %

      Zenpep®



      -




      288.0




      1.2




      -




      289.2




      -




      237.3




      0.4




      -




      237.7




      51.5




      21.7

      %

      Canasa®/Salofalk®



      -




      31.5




      16.8




      -




      48.3




      -




      169.2




      17.6




      -




      186.8




      (138.5)




      (74.1)

      %

      Vraylar®



      -




      857.5




      -




      -




      857.5




      -




      487.1




      -




      -




      487.1




      370.4




      76.0

      %

      Saphris®



      -




      135.3




      -




      -




      135.3




      -




      139.7




      -




      -




      139.7




      (4.4)




      (3.1)

      %

      Viberzi®



      -




      187.9




      1.6




      -




      189.5




      -




      176.5




      1.3




      -




      177.8




      11.7




      6.6

      %

      Teflaro®



      -




      147.0




      6.0




      -




      153.0




      -




      128.0




      0.3




      -




      128.3




      24.7




      19.3

      %

      Namzaric®



      -




      88.6




      -




      -




      88.6




      -




      115.8




      -




      -




      115.8




      (27.2)




      (23.5)

      %

      Rapaflo®



      23.5




      -




      6.0




      -




      29.5




      81.9




      -




      6.4




      -




      88.3




      (58.8)




      (66.6)

      %

      Skin Care



      158.0




      -




      14.6




      -




      172.6




      138.8




      -




      15.2




      -




      154.0




      18.6




      12.1

      %

      Kybella®/Belkyra®



      27.4




      -




      3.3




      -




      30.7




      31.8




      -




      6.3




      -




      38.1




      (7.4)




      (19.4)

      %

      Dalvance®



      -




      81.9




      6.0




      -




      87.9




      -




      56.1




      2.3




      -




      58.4




      29.5




      50.5

      %

      Avycaz®



      -




      116.7




      -




      -




      116.7




      -




      94.6




      -




      -




      94.6




      22.1




      23.4

      %

      Liletta®



      -




      79.1




      -




      -




      79.1




      -




      50.9




      -




      -




      50.9




      28.2




      55.4

      %

      Namenda®



      -




      22.8




      -




      -




      22.8




      -




      71.0




      -




      -




      71.0




      (48.2)




      (67.9)

      %

      Armour Thyroid



      -




      218.5




      -




      -




      218.5




      -




      198.8




      -




      -




      198.8




      19.7




      9.9

      %

      Savella®



      -




      88.5




      -




      -




      88.5




      -




      85.0




      -




      -




      85.0




      3.5




      4.1

      %

      Other Products Revenues



      261.9




      797.6




      342.6




      32.0




      1,434.1




      308.9




      749.3




      380.2




      39.5




      1,477.9




      (43.8)




      (3.0)

      %

      Total Net Revenues


      $

      6,820.0



      $

      5,834.9



      $

      3,402.0



      $

      32.0




      16,088.9



      $

      6,920.3



      $

      5,322.9



      $

      3,504.7



      $

      39.5




      15,787.4



      $

      301.5




      1.9

      %




















































































































































      1Botox® is comprised of the following:

















































      Botox® Therapeutics



      1,739.2




      -




      389.1




      -




      2,128.3




      1,638.5




      -




      390.4




      -




      2,028.9




      99.4




      4.9

      %

      Botox® Cosmetics



      991.3




      -




      671.7




      -




      1,663.0




      907.3




      -




      641.2




      -




      1,548.5




      114.5




      7.4

      %


















































       

      The following table presents Allergan plc's Condensed Consolidated Balance Sheets as of December 31, 2019 and December 31, 2018.


      Table 3


      ALLERGAN PLC


      CONDENSED CONSOLIDATED BALANCE SHEETS


      (Unaudited; in millions)




      December 31,



      December 31,




      2019



      2018




















      Assets









      Cash and cash equivalents


      $

      2,503.3



      $

      880.4


      Marketable securities



      3,411.6




      1,026.9


      Accounts receivable, net



      3,192.3




      2,868.1


      Inventories



      1,133.1




      846.9


      Prepaid expenses and other current assets



      886.4




      819.1


      Assets held for sale



      31.7




      916.2


      Property, plant and equipment, net



      1,926.5




      1,787.0


      Investments and other assets



      984.9




      3,034.3


      Right of use asset - operating leases



      490.4




      -


      Product rights and other intangibles



      37,890.6




      43,695.4


      Goodwill



      42,248.3




      45,913.3


      Total assets


      $

      94,699.1



      $

      101,787.6











      Liabilities & Equity









      Current liabilities


      $

      6,413.8



      $

      4,859.6


      Lease liability



      570.5



      $

      -


      Current and long-term debt and capital leases



      22,649.0




      23,797.7


      Deferred income taxes and other liabilities



      6,869.4




      7,999.3


      Total equity



      58,196.4




      65,131.0


      Total liabilities and equity


      $

      94,699.1



      $

      101,787.6


       

       

      The following table presents Allergan plc's Condensed Consolidated Statements of Cash Flows for the three and twelve months ended December 31, 2019 and 2018.


      Table 4


      ALLERGAN PLC








      CONSOLIDATED STATEMENTS OF CASH FLOWS








      (Unaudited; in millions)










      Three Months Ended December 31,



      Twelve Months Ended December 31,




      2019



      2018



      2019



      2018


      Cash Flows From Operating Activities:

















      Net (loss)


      $

      (317.3)



      $

      (4,295.9)



      $

      (5,265.1)



      $

      (5,086.2)


      Reconciliation to net cash provided by operating activities:

















      Depreciation



      53.9




      46.6




      204.5




      196.3


      Amortization



      1,517.5




      1,569.1




      5,856.6




      6,552.3


      Provision for inventory reserve



      32.4




      21.5




      160.2




      96.4


      Share-based compensation



      52.6




      54.6




      214.3




      239.8


      Deferred income tax benefit



      (295.6)




      107.1




      (660.9)




      (1,255.7)


      In-process research and development impairments



      -




      6.6




      436.0




      804.6


      Loss on asset sales and impairments, net



      314.0




      5,426.4




      3,993.0




      5,698.7


      Gain on forward sale of Teva shares



      -




      -




      -




      (60.9)


      Gain on sale of businesses



      -




      -




      -




      (182.6)


      Non-cash extinguishment of debt



      -




      12.6




      0.2




      30.0


      Cash charge related to extinguishment of debt



      -




      (27.4)




      -




      (45.6)


      Amortization of deferred financing costs



      4.2




      5.2




      17.5




      22.6


      Non-cash lease expense



      37.4




      -




      130.9




      -


      Contingent consideration adjustments,
         including accretion



      4.6




      6.6




      54.1




      (106.5)


      Other, net



      (3.2)




      28.5




      (5.5)




      29.0


      Changes in assets and liabilities (net of effects
         of acquisitions):

















      Decrease / (increase) in accounts receivable, net



      (174.2)




      (54.0)




      (358.8)




      (37.0)


      Decrease / (increase) in inventories



      (64.5)




      (9.5)




      (393.4)




      (145.7)


      Decrease / (increase) in prepaid expenses
         and other current assets



      (41.9)




      9.7




      (78.1)




      4.3


      Increase / (decrease) in accounts payable
         and accrued expenses



      559.5




      197.7




      1,434.4




      151.6


      Increase / (decrease) in income and other
         taxes payable



      59.2




      (1,607.1)




      1,697.9




      (1,191.6)


      Increase / (decrease) in other assets and liabilities



      (68.3)




      0.3




      (199.1)




      (73.7)


      Net cash provided by operating activities



      1,670.3




      1,498.6




      7,238.7




      5,640.1


      Cash Flows From Investing Activities:

















      Additions to property, plant and equipment



      (121.9)




      (88.4)




      (375.2)




      (253.5)


      Additions to product rights and other intangibles



      (12.3)




      -




      (58.3)




      -


      Additions to investments



      (200.0)




      (1,015.3)




      (3,938.0)




      (2,471.7)


      Proceeds from sale of investments and other assets



      102.9




      58.0




      1,569.6




      6,259.3


      Payments to settle Teva related matters



      -




      -




      -




      (466.0)


      Proceeds from sales of property, plant and equipment



      5.2




      5.8




      23.7




      30.4


      Acquisitions of businesses, net of cash acquired



      -




      -




      (80.6)




      -


      Net cash (used in) / provided by investing activities



      (226.1)




      (1,039.9)




      (2,858.8)




      3,098.5


      Cash Flows From Financing Activities:

















      Proceeds from borrowings on long-term indebtedness, including credit

         facility



      8.6




      1,939.8




      11.9




      2,657.0


      Proceeds from Forward Sale of Teva securities



      -




      -




      -




      465.5


      Debt issuance and other financing costs



      -




      (10.4)




      -




      (10.4)


      Payments on debt, including capital lease obligations



      -




      (1,688.6)




      (1,044.9)




      (8,804.5)


      Proceeds from stock plans



      46.2




      4.2




      91.2




      102.4


      Other financing, including contingent consideration



      (3.0)




      (9.2)




      (9.3)




      (30.9)


      Payments to settle Teva related matters



      -




      -




      -




      (234.0)


      Repurchase of ordinary shares



      (6.3)




      (751.9)




      (840.6)




      (2,775.4)


      Dividends



      (243.0)




      (241.7)




      (974.4)




      (1,049.8)


      Net cash (used in) financing activities



      (197.5)




      (757.8)




      (2,766.1)




      (9,680.1)


      Effect of currency exchange rate changes on cash

         and cash equivalents



      19.1




      (8.4)




      9.1




      4.7


      Net increase / (decrease) in cash and cash equivalents



      1,265.8




      (307.5)




      1,622.9




      (936.8)


      Cash and cash equivalents at beginning of period



      1,237.5




      1,187.9




      880.4




      1,817.2


      Cash and cash equivalents at end of period


      $

      2,503.3



      $

      880.4



      $

      2,503.3



      $

      880.4


       


      Non-GAAP performance net income per share is used by management as one of the primary metrics in evaluating the Company's performance.  We believe that Non-GAAP performance net income per share enhances the comparability of our results between periods and provides additional information and transparency to investors on adjustments and other items that are not indicative of the Company's current and future operating performance.  These are the financial measures used by our management team to evaluate our operating performance and make day to day operating decisions.  We define non-GAAP adjustments to the reported GAAP measures as GAAP results adjusted for the following net of tax: (i) amortization expenses, (ii) global supply chain and operational excellence initiatives or other restructurings of a similar nature, (iii) acquisition, divestiture, integration and licensing charges, (iv) accretion and fair market value adjustments on contingent liabilities, (v) impairment/asset sales and related costs, including the exclusion of discontinued operations, (vi) legal settlements and (vii) other unusual charges or expenses.  Non-GAAP performance net income per share is not, and should not be viewed as, a substitute for reported GAAP continuing operations loss per share.  The Company has consistently excluded amortization of all intangible assets, including the product rights that generate a significant portion of our ongoing revenue. The Company's total accumulated amortization, including impairments of currently marketed products, related to our intangible assets as of December 31, 2019 and December 31, 2018 was $39.6 billion and $32.3 billion, respectively, and is expected to continue to be a material non-GAAP adjustment.  The following table presents Allergan plc's GAAP to Non-GAAP adjustments for the three and twelve months ended December 31, 2019 and 2018:


      Table 5


      ALLERGAN PLC


      GAAP TO NON-GAAP ADJUSTMENTS


      (Unaudited; in millions)













































      Three Months Ended December 31, 2019




      Net

      Revenue



      COGS



      Research &

      Development



      Selling &

      Marketing



      General &

      Administrative



      Amortization



      Asset sales & Impairments, net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      4,351.0



      $

      704.0



      $

      452.5



      $

      883.0



      $

      756.6



      $

      1,517.5



      $

      314.0



      $

      (166.6)



      $

      21.2



      $

      (104.7)











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (0.2)




      (0.2)




      (0.6)




      (0.2)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (2.3)




      0.1




      (1.4)




      4.2




      -




      -




      -




      -




      -


      Costs associated with disposed businesses



      -




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      (0.3)




      (4.9)




      (0.7)




      (13.2)




      -




      -




      -




      -




      -


      Costs associated with the AbbVie transaction



      -




      (4.1)




      (3.1)




      (31.2)




      (34.5)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Other



      -




      -




      (27.1)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      (2.2)




      (2.4)




      -




      -




      -




      -




      -




      -




      -


      Impairment of Carafate intangible asset



      -




      -




      -




      -




      -




      -




      (314.0)




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (5.8)




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (401.6)




      -




      -




      -




      -




      -


      Other adjustments



      -




      (0.1)




      (0.1)




      -




      1.8




      (1,517.5)




      -




      -




      -




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      239.9


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      63.2











































      Non-GAAP Adjusted


      $

      4,351.0



      $

      694.8



      $

      414.8



      $

      849.1



      $

      313.1



      $

      -



      $

      -



      $

      (172.4)



      $

      21.2



      $

      198.4










































































































































































































































































































































































































































































































































































































































































































































































































































































































































      Three Months Ended December 31, 2018




      Net

      Revenue



      COGS



      Research & Development



      Selling & Marketing



      General & Administrative



      Amortization



      Asset sales &
      Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      4,079.7



      $

      590.0



      $

      678.1



      $

      841.6



      $

      352.0



      $

      1,569.1



      $

      5,433.0



      $

      (198.6)



      $

      (9.9)



      $

      (1,296.7)











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (0.3)




      (0.6)




      (1.4)




      (0.4)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      (0.6)




      -




      (2.5)




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (5.2)




      (0.1)




      (20.3)




      0.2




      -




      -




      -




      -




      -


      Costs associated with disposed businesses



      -




      0.5




      -




      0.2




      (1.3)




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      (0.1)




      0.2




      -




      (10.4)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Bonti, Inc.



      -




      -




      (196.6)




      -




      -




      -




      -




      -




      -




      -


      Editas Medicine, Inc.



      -




      -




      (25.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (16.5)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      (3.7)




      (2.9)




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (5.5)




      -




      -


      Impairment of Kybella® intangible asset



      -




      -




      -




      -




      -




      -




      (1,643.8)




      -




      -




      -


      Impairment of TrueTear® intangible asset



      -




      -




      -




      -




      -




      -




      (187.6)




      -




      -




      -


      Impairment of goodwill



      -




      -




      -




      -




      -




      -




      (2,841.1)




      -




      -




      -


      Impairment of Anti-Infectives held for sale



      -




      -




      -




      -




      -




      -




      (771.7)




      -




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      25.5




      -




      -




      -


      Impairment of assets held for sale



      -




      -




      -




      -




      -




      -




      (14.2)




      -




      -




      -


      Loss on bond repurchases



      -




      -




      -




      -




      -




      -




      -




      -




      (13.9)




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (16.4)




      -




      -




      -




      -




      -


      Other adjustments



      -




      0.1




      0.1




      -




      (0.9)




      (1,569.1)




      (0.1)




      (0.1)




      (2.0)




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      658.8


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      879.8











































      Non-GAAP Adjusted


      $

      4,079.7



      $

      581.3



      $

      436.1



      $

      820.1



      $

      320.3



      $

      -



      $

      -



      $

      (204.2)



      $

      (25.8)



      $

      241.9











































      The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the three months ended December 31, 2019 was impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate, partially offset by U.S. income taxed at rates higher than the Irish statutory rate.

       

      The non-GAAP effective tax rate for the three months ended December 31, 2019 excludes a net discrete tax benefit of $63.2 million related to a change in valuation allowance and the tax effects of integration activities.
























































































































































































































































































































































































































































































































































































































































































































































































































































      Twelve Months Ended December 31, 2019




      Net

      Revenue



      COGS



      Research &

      Development



      Selling &

      Marketing



      General &

      Administrative



      Amortization



      Asset sales &

      Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      16,088.9



      $

      2,493.1



      $

      1,812.0



      $

      3,461.7



      $

      2,481.8



      $

      5,856.6



      $

      4,429.0



      $

      (706.2)



      $

      32.8



      $

      146.4











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (0.9)




      (1.1)




      (2.8)




      (0.9)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      -




      -




      (0.8)




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (8.3)




      0.9




      (4.0)




      (4.3)




      -




      -




      -




      -




      -


      Costs associated with disposed businesses



      -




      -




      -




      -




      (0.3)




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      (0.2)




      (5.4)




      (1.5)




      (23.2)




      -




      -




      -




      -




      -


      Costs associated with the AbbVie transaction



      -




      (4.6)




      (5.0)




      (49.9)




      (86.7)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Akarna Therapeutics, Ltd



      -




      -




      (10.0)




      -




      -




      -




      -




      -




      -




      -


      RetroSense Therapeutics, LLC



      -




      -




      (20.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (53.2)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      (44.6)




      (9.5)




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (22.2)




      -




      -


      Impairment of goodwill



      -




      -




      -




      -




      -




      -




      (3,552.8)




      -




      -




      -


      Impairment of Anti-Infectives



      -




      -




      -




      -




      -




      -




      (129.4)




      -




      -




      -


      Impairment of IPR&D products acquired in the Allergan
      Acquisition



      -




      -




      -




      -




      -




      -




      (182.0)




      -




      -




      -


      Impairment of IPR&D products acquired in the Vitae
      Acquisition



      -




      -




      -




      -




      -




      -




      (78.0)




      -




      -




      -


      Impairment of IPR&D products acquired in the Tobira
      Acquisition



      -




      -




      -




      -




      -




      -




      (176.0)




      -




      -




      -


      Impairment of Carafate intangible asset



      -




      -




      -




      -




      -




      -




      (314.0)




      -




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      3.2




      -




      -




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (1,167.3)




      -




      -




      -




      -




      -


      Milestone component of ongoing intellectual property
      agreement



      (25.0)




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Other adjustments



      -




      (0.2)




      (0.1)




      -




      (1.2)




      (5,856.6)




      -




      -




      (0.3)




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      1,022.5


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      (394.0)











































      Non-GAAP Adjusted


      $

      16,063.9



      $

      2,434.3



      $

      1,708.6



      $

      3,403.5



      $

      1,197.1



      $

      -



      $

      -



      $

      (728.4)



      $

      32.5



      $

      774.9




















































































































































































































































































































































































































































































































































































































































































      Twelve Months Ended December 31, 2018




      Net

      Revenue



      COGS



      Research & Development



      Selling & Marketing



      General & Administrative



      Amortization



      Asset sales &

       Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      15,787.4



      $

      2,191.4



      $

      2,266.2



      $

      3,250.6



      $

      1,271.2



      $

      6,552.3



      $

      6,503.3



      $

      (866.0)



      $

      256.7



      $

      (1,770.7)











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (2.1)




      (4.8)




      (8.6)




      (2.9)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      (0.6)




      (0.7)




      (3.3)




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (33.7)




      (1.9)




      (38.8)




      (5.4)




      -




      (13.6)




      -




      -




      -


      Costs associated with disposed businesses



      -




      (1.0)




      -




      0.2




      (4.1)




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      (0.3)




      (0.6)




      (1.0)




      (43.5)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Elastagen Pty Ltd



      -




      -




      (96.1)




      -




      -




      -




      -




      -




      -




      -


      AstraZeneca plc



      -




      -




      (90.0)




      -




      -




      -




      -




      -




      -




      -


      Merck & Co.



      -




      -




      (115.0)




      -




      -




      -




      -




      -




      -




      -


      Chase Pharmaceuticals Corporation



      -




      -




      (75.0)




      -




      -




      -




      -




      -




      -




      -


      Repros Therapeutics, Inc.



      -




      -




      (33.2)




      -




      -




      -




      -




      -




      -




      -


      Bonti, Inc.



      -




      -




      (196.6)




      -




      -




      -




      -




      -




      -




      -


      Editas Medicine, Inc.



      -




      -




      (40.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (33.0)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      111.7




      (5.1)




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (21.2)




      -




      -


      Impairment of Kybella® intangible asset



      -




      -




      -




      -




      -




      -




      (1,643.8)




      -




      -




      -


      Impairment of TrueTear® intangible asset



      -




      -




      -




      -




      -




      -




      (187.6)




      -




      -




      -


      Impairment of goodwill



      -




      -




      -




      -




      -




      -




      (2,841.1)




      -




      -




      -


      Impairment of Anti-Infectives held for sale



      -




      -




      -




      -




      -




      -




      (771.7)




      -




      -




      -


      Impairment of IPR&D products acquired in the Allergan
      Acquisition



      -




      -




      -




      -




      -




      -




      (236.0)




      -




      -




      -


      Impairment of IPR&D products acquired in the Vitae
      Acquisition



      -




      -




      -




      -




      -




      -




      (40.0)




      -




      -




      -


      Impairment of assets held for sale



      -




      -




      -




      -




      -




      -




      (266.2)




      -




      -




      -


      Impairment of RORgt IPR&D product



      -




      -




      -




      -




      -




      -




      (522.0)




      -




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      18.4




      -




      -




      -


      Gain on Teva securities



      -




      -




      -




      -




      -




      -




      -




      -




      (60.6)




      -


      Milestone component of ongoing intellectual property
      agreement



      (25.0)




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Gain on the sale of divestiture



      -




      -




      -




      -




      -




      -




      -




      -




      (182.6)




      -


      Gain on bond repurchases



      -




      -




      -




      -




      -




      -




      -




      -




      (15.6)




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (56.8)




      -




      -




      -




      -




      -


      Other adjustments



      -




      0.1




      0.2




      -




      (2.0)




      (6,552.3)




      0.3




      (0.1)




      (5.7)




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      1,506.1


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      1,213.8











































      Non-GAAP Adjusted


      $

      15,762.4



      $

      2,266.1



      $

      1,574.5



      $

      3,201.7



      $

      1,153.2



      $

      -



      $

      -



      $

      (887.3)



      $

      (7.8)



      $

      949.2











































      The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the twelve months ended December 31, 2019 was impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate, partially offset by U.S. income taxed at rates higher than the Irish statutory rate.

       

      The non-GAAP effective tax rate for the twelve months ended December 31, 2019 excludes a net discrete tax detriment of $394.0 million related to a change in valuation allowance partially offset by the tax impacts of U.S. capital losses and changes in the applicable tax rates on certain temporary differences.











































       

      The following table presents a reconciliation of Allergan plc's reported net income / (loss) attributable to shareholders and diluted earnings per share to non-GAAP performance net income and non-GAAP performance net income per share for the three and twelve months ended December 31, 2019 and 2018:


      Table 6


      ALLERGAN PLC








      RECONCILIATION TABLE








      (Unaudited; in millions except per share amounts)



























      Three Months Ended



      Twelve Months Ended




      December 31,



      December 31,




      2019



      2018



      2019



      2018




































      GAAP to Non-GAAP Performance net income calculation


































      GAAP (loss) attributable to ordinary shareholders


      $

      (317.2)



      $

      (4,299.9)



      $

      (5,271.0)



      $

      (5,096.4)


      Adjusted for:

















      Amortization



      1,517.5




      1,569.1




      5,856.6




      6,552.3


      Acquisition, divestiture and licensing (income) /
      charges



      112.9




      249.9




      220.5




      485.7


      Accretion and fair-value adjustments to contingent
      consideration



      4.6




      6.6




      54.1




      (106.6)


      Goodwill and other impairments and asset sales, net
      and related costs



      314.0




      5,433.0




      4,429.0




      6,503.3


      Other



      -




      (15.9)




      -




      (42.6)


      Non-acquisition restructurings, including Global Supply
      Chain initiatives



      (0.6)




      25.4




      15.7




      79.8


      Legal settlements



      401.6




      16.4




      1,167.3




      56.8


      Income taxes on items above and other discrete
      income tax adjustments



      (303.1)




      (1,538.6)




      (628.5)




      (2,719.9)


      Non-GAAP performance net income attributable to
      shareholders


      $

      1,729.7



      $

      1,446.0



      $

      5,843.7



      $

      5,712.4



















      Diluted earnings per share


































      Diluted (loss) per share from continuing operations
      attributable to shareholders- GAAP


      $

      (0.97)



      $

      (12.83)



      $

      (16.02)



      $

      (15.12)



















      Non-GAAP performance net income per share attributable
      to shareholders


      $

      5.22



      $

      4.29



      $

      17.64



      $

      16.69



















      Basic weighted average ordinary shares outstanding



      328.4




      335.1




      329.0




      337.0


      Effect of dilutive securities:

















      Dilutive shares



      2.9




      2.3




      2.2




      5.2


      Diluted weighted average ordinary shares outstanding



      331.3




      337.4




      331.2




      342.2


















       

       

      We define adjusted EBITDA as an amount equal to consolidated net income / (loss) attributable to shareholders for such period adjusted for the following: (i) interest expense, (ii) interest income, (iii) (benefit) for income taxes, (iv) depreciation and amortization expenses, (v) stock-based compensation expense, (vi) asset impairment charges and losses / (gains) and expenses associated with the sale of assets, including the exclusion of discontinued operations, (vii) business restructuring charges associated with Allergan's global supply chain and operational excellence initiatives or other restructurings of a similar nature, (viii) costs and charges associated with the acquisition and divestitures of businesses and assets including, but not limited to, milestone payments, integration charges, other charges associated with the revaluation of assets or liabilities and charges associated with the revaluation of acquisition related contingent liabilities that are based in whole or in part on future estimated cash flows, (ix) litigation charges and settlements and (x) other unusual charges or expenses. We define non-GAAP adjusted operating income as adjusted EBITDA including depreciation and certain stock-based compensation charges and excluding dividend income and fair value accounting results included within other income (expense), net.

       

      The following table presents a reconciliation of Allergan plc's reported net income / (loss) attributable to shareholders for the three and twelve months ended December 31, 2019 and 2018 to adjusted EBITDA and non-GAAP operating income:



      Table 7



      ALLERGAN PLC









      ADJUSTED EBITDA and NON-GAAP OPERATING INCOME, RECONCILIATION TABLE









      (Unaudited; in millions)




















      Three Months Ended



      Twelve Months Ended





      December 31,



      December 31,





      2019



      2018



      2019



      2018







































      GAAP (loss) attributable to ordinary shareholders


      $

      (317.2)



      $

      (4,299.9)



      $

      (5,271.0)



      $

      (5,096.4)



      Plus:


















      Interest expense



      191.9




      210.2




      783.0




      911.2



      Interest income



      (25.3)




      (11.6)




      (76.8)




      (45.2)



      Provision / (benefit) for income taxes



      (104.7)




      (1,296.7)




      146.4




      (1,770.7)



      Depreciation



      53.9




      46.6




      204.5




      196.3



      Amortization



      1,517.5




      1,569.1




      5,856.6




      6,552.3



      EBITDA


      $

      1,316.1



      $

      (3,782.3)



      $

      1,642.7



      $

      747.5



      Adjusted for:


















      Acquisition, divestiture and licensing charges



      117.5




      252.7




      237.0




      480.3



      Goodwill and other impairments and asset sales, net and
      related costs



      314.0




      5,433.0




      4,429.0




      6,503.3



      Other



      -




      (15.9)




      -




      (42.6)



      Non-acquisition restructurings, including Global Supply Chain
      initiatives, excluding depreciation



      (0.6)




      25.4




      15.7




      75.6



      Legal settlements



      401.6




      16.4




      1,167.3




      56.8



      Accretion and fair-value adjustments to contingent consideration



      4.6




      6.6




      54.1




      (106.6)



      Share-based compensation including cash settlements



      52.6




      54.6




      214.3




      239.8



      Adjusted EBITDA


      $

      2,205.8



      $

      1,990.5



      $

      7,760.1



      $

      7,954.1



      Adjusted for:


















      Depreciation



      (53.9)




      (46.6)




      (204.5)




      (192.1)



      Other income (expense) related to fair value accounting



      (21.2)




      25.8




      (32.5)




      7.0



      Share-based compensation not related to restructuring
      charges and purchase accounting impact on stock-based
      compensation for acquired awards



      (51.4)




      (51.9)




      (208.6)




      (213.2)



      Non-GAAP Operating Income


      $

      2,079.3



      $

      1,917.8



      $

      7,314.5



      $

      7,555.8



       

       

      The following table details Allergan plc's segment contribution reconciled to the non-GAAP contribution for the same financial statement line items for the three and twelve months ended December 31, 2019 and 2018.





































































































      Table 8


      ALLERGAN PLC


      Segment Contribution to Non-GAAP Allergan plc Contribution


      (Unaudited; $ in millions)













































      Three Months Ended December 31, 2019



      Three Months Ended December 31, 2018



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total


      Net revenues

      $

      1,821.2



      $

      1,610.7



      $

      917.7



      $

      1.4



      $

      4,351.0



      $

      1,808.8



      $

      1,397.9



      $

      870.2



      $

      2.8



      $

      4,079.7


      Operating expenses:








































      Cost of sales(1)


      156.0




      287.8




      148.4




      102.6




      694.8




      139.3




      195.1




      146.1




      100.8




      581.3


      Selling and marketing


      376.1




      256.4




      216.6




      -




      849.1




      378.1




      211.1




      230.8




      0.1




      820.1


      General and administrative


      47.8




      41.5




      36.9




      186.9




      313.1




      59.7




      45.1




      41.3




      174.2




      320.3


      Segment contribution

      $

      1,241.3



      $

      1,025.0



      $

      515.8



      $

      (288.1)



      $

      2,494.0



      $

      1,231.7



      $

      946.6



      $

      452.0



      $

      (272.3)



      $

      2,358.0


      Segment margin


      68.2

      %



      63.6

      %



      56.2

      %


      n.m.




      57.3

      %



      68.1

      %



      67.7

      %



      51.9

      %


      n.m.




      57.8

      %

      Segment gross margin(2)


      91.4

      %



      82.1

      %



      83.8

      %


      n.m.




      84.0

      %



      92.3

      %



      86.0

      %



      83.2

      %


      n.m.




      85.8

      %










































      (1) Excludes amortization and impairment of acquired intangibles including product rights.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.













































      Twelve Months Ended December 31, 2019



      Twelve Months Ended December 31, 2018



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total


      Net revenues

      $

      6,820.0



      $

      5,834.9



      $

      3,402.0



      $

      7.0



      $

      16,063.9



      $

      6,920.3



      $

      5,322.9



      $

      3,504.7



      $

      14.5



      $

      15,762.4


      Operating expenses:








































      Cost of sales(1)


      578.2




      954.8




      548.3




      353.0




      2,434.3




      565.2




      799.1




      537.1




      364.7




      2,266.1


      Selling and marketing


      1,490.4




      978.2




      934.7




      0.2




      3,403.5




      1,348.3




      924.6




      928.7




      0.1




      3,201.7


      General and administrative


      190.1




      160.7




      117.0




      729.3




      1,197.1




      205.3




      156.4




      141.7




      649.8




      1,153.2


      Segment contribution

      $

      4,561.3



      $

      3,741.2



      $

      1,802.0



      $

      (1,075.5)



      $

      9,029.0



      $

      4,801.5



      $

      3,442.8



      $

      1,897.2



      $

      (1,000.1)



      $

      9,141.4


      Segment margin


      66.9

      %



      64.1

      %



      53.0

      %


      n.m.




      56.2

      %



      69.4

      %



      64.7

      %



      54.1

      %


      n.m.




      58.0

      %

      Segment gross margin(2)


      91.5

      %



      83.6

      %



      83.9

      %


      n.m.




      84.8

      %



      91.8

      %



      85.0

      %



      84.7

      %


      n.m.




      85.6

      %










































      (1) Excludes amortization and impairment of acquired intangibles including product rights.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.











































      The following table details Allergan plc's product revenue for significant promoted products within the US Specialized Therapeutics segment for the three and twelve months ended December 31, 2019 and 2018.


      Table 9


      ALLERGAN PLC


      US Specialized Therapeutics Product Revenue


      (Unaudited; in millions)
















      Three Months Ended December 31,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      587.0



      $

      587.3



      $

      (0.3)




      (0.1)

      %

      Restasis®



      309.0




      325.0




      (16.0)




      (4.9)

      %

      Alphagan®/Combigan®



      94.5




      97.7




      (3.2)




      (3.3)

      %

      Lumigan®/Ganfort®



      81.9




      74.0




      7.9




      10.7

      %

      Ozurdex®



      31.6




      29.3




      2.3




      7.8

      %

      Eye Drops



      61.2




      47.9




      13.3




      27.8

      %

      Other Eye Care



      8.8




      13.4




      (4.6)




      (34.3)

      %

      Total Medical Aesthetics



      742.2




      738.3




      3.9




      0.5

      %

      Facial Aesthetics



      444.5




      423.7




      20.8




      4.9

      %

      Botox® Cosmetics



      271.8




      258.1




      13.7




      5.3

      %

      Juvederm® Collection



      166.4




      158.4




      8.0




      5.1

      %

      Kybella®



      6.3




      7.2




      (0.9)




      (12.5)

      %

      Plastic Surgery



      67.1




      68.2




      (1.1)




      (1.6)

      %

      Breast Implants



      67.1




      68.2




      (1.1)




      (1.6)

      %

      Regenerative Medicine



      132.7




      124.7




      8.0




      6.4

      %

      Alloderm®



      104.7




      94.9




      9.8




      10.3

      %

      Other Regenerative Medicine



      28.0




      29.8




      (1.8)




      (6.0)

      %

      Body Contouring



      53.3




      81.3




      (28.0)




      (34.4)

      %

      Coolsculpting® Systems & Add On
      Applicators



      16.9




      26.8




      (9.9)




      (36.9)

      %

      Coolsculpting® Consumables



      36.4




      54.5




      (18.1)




      (33.2)

      %

      Skin Care(3)



      44.6




      40.4




      4.2




      10.4

      %

      Total Medical Dermatology



      13.0




      4.5




      8.5




      188.9

      %

      Aczone®



      2.5




      0.6




      1.9



      n.m.


      Other Medical Dermatology(4)



      10.5




      3.9




      6.6




      169.2

      %

      Total Neuroscience & Urology



      465.0




      452.2




      12.8




      2.8

      %

      Botox® Therapeutics



      463.0




      433.3




      29.7




      6.9

      %

      Rapaflo®



      2.0




      18.9




      (16.9)




      (89.4)

      %

      Other Revenues



      14.0




      26.5




      (12.5)




      (47.2)

      %

      Net Revenues


      $

      1,821.2



      $

      1,808.8



      $

      12.4




      0.7

      %


















      Operating expenses:

















      Cost of sales(1)



      156.0




      139.3




      16.7




      12.0

      %

      Selling and marketing



      376.1




      378.1




      (2.0)




      (0.5)

      %

      General and administrative



      47.8




      59.7




      (11.9)




      (19.9)

      %

      Segment contribution


      $

      1,241.3



      $

      1,231.7



      $

      9.6




      0.8

      %

      Segment margin



      68.2

      %



      68.1

      %







      0.1

      %

      Segment gross margin(2)



      91.4

      %



      92.3

      %







      (0.9)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes SkinMedica® and Latisse®.


      (4) Includes Tazorac® sales of $0.3 million which were previously disclosed separately in the three months ended December 31, 2018.
























































































































































      Twelve Months Ended December 31,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      2,182.4



      $

      2,235.7



      $

      (53.3)




      (2.4)

      %

      Restasis®



      1,138.4




      1,197.0




      (58.6)




      (4.9)

      %

      Alphagan®/Combigan®



      360.0




      375.4




      (15.4)




      (4.1)

      %

      Lumigan®/Ganfort®



      269.2




      291.8




      (22.6)




      (7.7)

      %

      Ozurdex®



      125.5




      111.0




      14.5




      13.1

      %

      Eye Drops



      230.4




      202.7




      27.7




      13.7

      %

      Other Eye Care



      58.9




      57.8




      1.1




      1.9

      %

      Total Medical Aesthetics



      2,772.0




      2,774.6




      (2.6)




      (0.1)

      %

      Facial Aesthetics



      1,606.2




      1,487.3




      118.9




      8.0

      %

      Botox® Cosmetics



      991.3




      907.3




      84.0




      9.3

      %

      Juvederm® Collection



      587.5




      548.2




      39.3




      7.2

      %

      Kybella®



      27.4




      31.8




      (4.4)




      (13.8)

      %

      Plastic Surgery



      254.4




      263.0




      (8.6)




      (3.3)

      %

      Breast Implants



      254.4




      263.0




      (8.6)




      (3.3)

      %

      Regenerative Medicine



      505.3




      523.9




      (18.6)




      (3.6)

      %

      Alloderm®



      395.9




      407.3




      (11.4)




      (2.8)

      %

      Other Regenerative Medicine



      109.4




      116.6




      (7.2)




      (6.2)

      %

      Body Contouring



      248.1




      361.6




      (113.5)




      (31.4)

      %

      Coolsculpting® Systems & Add On
      Applicators



      62.8




      126.3




      (63.5)




      (50.3)

      %

      Coolsculpting® Consumables



      185.3




      235.3




      (50.0)




      (21.2)

      %

      Skin Care(3)



      158.0




      138.8




      19.2




      13.8

      %

      Total Medical Dermatology



      44.0




      115.5




      (71.5)




      (61.9)

      %

      Aczone®



      9.3




      55.1




      (45.8)




      (83.1)

      %

      Other Medical Dermatology(4)



      34.7




      60.4




      (25.7)




      (42.5)

      %

      Total Neuroscience & Urology



      1,762.7




      1,720.4




      42.3




      2.5

      %

      Botox® Therapeutics



      1,739.2




      1,638.5




      100.7




      6.1

      %

      Rapaflo®



      23.5




      81.9




      (58.4)




      (71.3)

      %

      Other Revenues



      58.9




      74.1




      (15.2)




      (20.5)

      %

      Net Revenues


      $

      6,820.0



      $

      6,920.3



      $

      (100.3)




      (1.4)

      %


















      Operating expenses:

















      Cost of sales(1)



      578.2




      565.2




      13.0




      2.3

      %

      Selling and marketing



      1,490.4




      1,348.3




      142.1




      10.5

      %

      General and administrative



      190.1




      205.3




      (15.2)




      (7.4)

      %

      Segment contribution


      $

      4,561.3



      $

      4,801.5



      $

      (240.2)




      (5.0)

      %

      Segment margin



      66.9

      %



      69.4

      %







      (2.5)

      %

      Segment gross margin(2)



      91.5

      %



      91.8

      %







      (0.3)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes SkinMedica® and Latisse®.


      (4) Includes Tazorac® sales of $25.4 million which were previously disclosed separately in the twelve months ended December 31, 2018.




       

      The following table details Allergan plc's product revenue for significant promoted products within the US General Medicine segment for the three and twelve months ended December 31, 2019 and 2018.


      Table 10


      ALLERGAN PLC


      US General Medicine Product Revenue


      (Unaudited; in millions)
















      Three Months Ended December 31,



      Change




      2019



      2018



      Dollars



      %


      Total Central Nervous System (CNS)


      $

      457.0



      $

      316.1



      $

      140.9




      44.6

      %

      Vraylar®



      283.1




      150.5




      132.6




      88.1

      %

      Viibryd®/Fetzima®



      114.2




      95.5




      18.7




      19.6

      %

      Saphris®



      36.3




      36.8




      (0.5)




      (1.4)

      %

      Namzaric®



      20.2




      22.6




      (2.4)




      (10.6)

      %

      Namenda ®(3)



      3.2




      10.7




      (7.5)




      (70.1)

      %

      Total Gastrointestinal (GI)



      434.1




      449.8




      (15.7)




      (3.5)

      %

      Linzess®



      231.2




      205.2




      26.0




      12.7

      %

      Zenpep®



      80.8




      66.8




      14.0




      21.0

      %

      Carafate®/Sulcrate®



      46.9




      54.1




      (7.2)




      (13.3)

      %

      Viberzi®



      49.8




      48.9




      0.9




      1.8

      %

      Asacol®/Delzicol®



      8.5




      27.9




      (19.4)




      (69.5)

      %

      Canasa®/Salofalk®



      7.5




      38.8




      (31.3)




      (80.7)

      %

      Other GI



      9.4




      8.1




      1.3




      16.0

      %

      Total Women's Health



      232.8




      213.9




      18.9




      8.8

      %

      Lo Loestrin®



      156.2




      143.8




      12.4




      8.6

      %

      Liletta®



      22.5




      14.6




      7.9




      54.1

      %

      Other Women's Health(4)(5)



      54.1




      55.5




      (1.4)




      (2.5)

      %

      Total Anti-Infectives



      104.3




      78.8




      25.5




      32.4

      %

      Teflaro®



      38.1




      30.0




      8.1




      27.0

      %

      Avycaz®



      30.7




      24.6




      6.1




      24.8

      %

      Dalvance®



      26.4




      17.3




      9.1




      52.6

      %

      Other Anti-Infectives



      9.1




      6.9




      2.2




      31.9

      %

      Diversified Brands



      320.3




      300.1




      20.2




      6.7

      %

      Bystolic®/Byvalson®



      169.6




      151.7




      17.9




      11.8

      %

      Armour Thyroid



      57.4




      53.4




      4.0




      7.5

      %

      Savella®



      21.5




      23.6




      (2.1)




      (8.9)

      %

      Other Diversified Brands



      71.8




      71.4




      0.4




      0.6

      %

      Other Revenues



      62.2




      39.2




      23.0




      58.7

      %

      Net revenues


      $

      1,610.7



      $

      1,397.9



      $

      212.8




      15.2

      %


















      Operating expenses:

















      Cost of sales(1)



      287.8




      195.1




      92.7




      47.5

      %

      Selling and marketing



      256.4




      211.1




      45.3




      21.5

      %

      General and administrative



      41.5




      45.1




      (3.6)




      (8.0)

      %

      Segment contribution


      $

      1,025.0



      $

      946.6



      $

      78.4




      8.3

      %

      Segment margin



      63.6

      %



      67.7

      %







      (4.1)

      %

      Segment gross margin(2)



      82.1

      %



      86.0

      %







      (3.9)

      %

      (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes Namenda XR® and Namenda® IR.


      (4) Includes Estrace® Cream sales of $14.7 million which were previously disclosed separately in the three months ended December 31, 2018


      (5) Includes Minastrin® 24 sales of $2.9 million which were previously disclosed separately in the three months ended December 31, 2018

























































































      Twelve Months Ended December 31,



      Change




      2019



      2018



      Dollars



      %


      Total Central Nervous System (CNS)


      $

      1,516.3



      $

      1,156.0



      $

      360.3




      31.2

      %

      Vraylar®



      857.5




      487.1




      370.4




      76.0

      %

      Viibryd®/Fetzima®



      412.1




      342.4




      69.7




      20.4

      %

      Saphris®



      135.3




      139.7




      (4.4)




      (3.1)

      %

      Namzaric®



      88.6




      115.8




      (27.2)




      (23.5)

      %

      Namenda ®(3)



      22.8




      71.0




      (48.2)




      (67.9)

      %

      Total Gastrointestinal (GI)



      1,634.2




      1,723.7




      (89.5)




      (5.2)

      %

      Linzess®



      803.2




      761.1




      42.1




      5.5

      %

      Zenpep®



      288.0




      237.3




      50.7




      21.4

      %

      Carafate®/Sulcrate®



      212.5




      217.8




      (5.3)




      (2.4)

      %

      Viberzi®



      187.9




      176.5




      11.4




      6.5

      %

      Asacol®/Delzicol®



      76.7




      130.8




      (54.1)




      (41.4)

      %

      Canasa®/Salofalk®



      31.5




      169.2




      (137.7)




      (81.4)

      %

      Other GI



      34.4




      31.0




      3.4




      11.0

      %

      Total Women's Health



      895.7




      786.8




      108.9




      13.8

      %

      Lo Loestrin®



      588.9




      527.7




      61.2




      11.6

      %

      Liletta®



      79.1




      50.9




      28.2




      55.4

      %

      Other Women's Health(4)(5)



      227.7




      208.2




      19.5




      9.4

      %

      Total Anti-Infectives



      377.1




      304.4




      72.7




      23.9

      %

      Teflaro®



      147.0




      128.0




      19.0




      14.8

      %

      Avycaz®



      116.7




      94.6




      22.1




      23.4

      %

      Dalvance®



      81.9




      56.1




      25.8




      46.0

      %

      Other Anti-Infectives



      31.5




      25.7




      5.8




      22.6

      %

      Diversified Brands



      1,202.8




      1,156.0




      46.8




      4.0

      %

      Bystolic®/Byvalson®



      600.6




      583.8




      16.8




      2.9

      %

      Armour Thyroid



      218.5




      198.8




      19.7




      9.9

      %

      Savella®



      88.5




      85.0




      3.5




      4.1

      %

      Other Diversified Brands



      295.2




      288.4




      6.8




      2.4

      %

      Other Revenues



      208.8




      196.0




      12.8




      6.5

      %

      Net revenues


      $

      5,834.9



      $

      5,322.9



      $

      512.0




      9.6

      %


















      Operating expenses:

















      Cost of sales(1)



      954.8




      799.1




      155.7




      19.5

      %

      Selling and marketing



      978.2




      924.6




      53.6




      5.8

      %

      General and administrative



      160.7




      156.4




      4.3




      2.7

      %

      Segment contribution


      $

      3,741.2



      $

      3,442.8



      $

      298.4




      8.7

      %

      Segment margin



      64.1

      %



      64.7

      %







      (0.6)

      %

      Segment gross margin(2)



      83.6

      %



      85.0

      %







      (1.4)

      %

      (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes Namenda XR® and Namenda® IR.


      (4) Includes Estrace® Cream sales of $49.0 million which were previously disclosed separately in the twelve months ended December 31, 2018


      (5) Includes Minastrin® 24 sales of $9.5 million which were previously disclosed separately in the twelve months ended December 31, 2018





















       

      The following table details Allergan plc's product revenue for significant promoted products within the International segment for the three and twelve months ended December 31, 2019 and 2018.


      Table 11


      ALLERGAN PLC


      International Product Revenue


      (Unaudited; in millions)





















      Three Months Ended December 31,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      319.4



      $

      308.2



      $

      11.2




      3.6

      %

      Lumigan®/Ganfort®



      95.6




      96.9




      (1.3)




      (1.3)

      %

      Alphagan®/Combigan®



      43.1




      46.7




      (3.6)




      (7.7)

      %

      Ozurdex®



      66.7




      29.6




      37.1




      125.3

      %

      Eye Drops



      59.3




      71.7




      (12.4)




      (17.3)

      %

      Restasis®



      18.7




      16.6




      2.1




      12.7

      %

      Other Eye Care



      36.0




      46.7




      (10.7)




      (22.9)

      %

      Total Medical Aesthetics



      412.9




      396.0




      16.9




      4.3

      %

      Facial Aesthetics



      364.6




      332.8




      31.8




      9.6

      %

      Botox® Cosmetics



      182.9




      157.8




      25.1




      15.9

      %

      Juvederm® Collection



      180.9




      174.0




      6.9




      4.0

      %

      Belkyra® (Kybella®)



      0.8




      1.0




      (0.2)




      (20.0)

      %

      Plastic Surgery



      15.3




      10.8




      4.5




      41.7

      %

      Breast Implants



      15.1




      10.5




      4.6




      43.8

      %

      Other Plastic Surgery



      0.2




      0.3




      (0.1)




      (33.3)

      %

      Regenerative Medicine



      3.4




      3.9




      (0.5)




      (12.8)

      %

      Alloderm®



      2.0




      2.5




      (0.5)




      (20.0)

      %

      Other Regenerative Medicine



      1.4




      1.4




      0.0




      0.0

      %

      Body Contouring



      25.4




      44.9




      (19.5)




      (43.4)

      %

      Coolsculpting® Systems & Add On
      Applicators



      8.8




      21.5




      (12.7)




      (59.1)

      %

      Coolsculpting® Consumables



      16.6




      23.4




      (6.8)




      (29.1)

      %

      Skin Care



      4.2




      3.6




      0.6




      16.7

      %

      Botox® Therapeutics and Other



      168.8




      150.1




      18.7




      12.5

      %

      Botox® Therapeutics



      102.5




      96.7




      5.8




      6.0

      %

      Asacol®/Delzicol®



      8.9




      10.7




      (1.8)




      (16.8)

      %

      Constella®



      6.8




      6.4




      0.4




      6.3

      %

      Other Products



      50.6




      36.3




      14.3




      39.4

      %

      Other Revenues



      16.6




      15.9




      0.7




      4.4

      %

      Net revenues


      $

      917.7



      $

      870.2



      $

      47.5




      5.5

      %


















      Operating expenses:

















      Cost of sales(1)



      148.4




      146.1




      2.3




      1.6

      %

      Selling and marketing



      216.6




      230.8




      (14.2)




      (6.2)

      %

      General and administrative



      36.9




      41.3




      (4.4)




      (10.7)

      %

      Segment contribution


      $

      515.8



      $

      452.0



      $

      63.8




      14.1

      %

      Segment margin



      56.2

      %



      51.9

      %







      4.3

      %

      Segment gross margin(2)



      83.8

      %



      83.2

      %







      0.6

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.
















































































































































































      Twelve Months Ended December 31,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      1,251.1



      $

      1,294.6



      $

      (43.5)




      (3.4)

      %

      Lumigan®/Ganfort®



      360.8




      392.6




      (31.8)




      (8.1)

      %

      Alphagan®/Combigan®



      162.0




      176.0




      (14.0)




      (8.0)

      %

      Ozurdex®



      274.6




      187.7




      86.9




      46.3

      %

      Eye Drops



      235.8




      279.7




      (43.9)




      (15.7)

      %

      Restasis®



      50.2




      64.5




      (14.3)




      (22.2)

      %

      Other Eye Care



      167.7




      194.1




      (26.4)




      (13.6)

      %

      Total Medical Aesthetics



      1,480.8




      1,533.3




      (52.5)




      (3.4)

      %

      Facial Aesthetics



      1,331.1




      1,262.3




      68.8




      5.5

      %

      Botox® Cosmetics



      671.7




      641.2




      30.5




      4.8

      %

      Juvederm® Collection



      656.1




      614.8




      41.3




      6.7

      %

      Belkyra® (Kybella®)



      3.3




      6.3




      (3.0)




      (47.6)

      %

      Plastic Surgery



      1.8




      131.5




      (129.7)




      (98.6)

      %

      Breast Implants



      0.6




      130.1




      (129.5)




      (99.5)

      %

      Other Plastic Surgery



      1.2




      1.4




      (0.2)




      (14.3)

      %

      Regenerative Medicine



      14.6




      16.8




      (2.2)




      (13.1)

      %

      Alloderm®



      7.9




      8.0




      (0.1)




      (1.3)

      %

      Other Regenerative Medicine



      6.7




      8.8




      (2.1)




      (23.9)

      %

      Body Contouring



      118.7




      107.5




      11.2




      10.4

      %

      Coolsculpting®Systems & Add On
      Applicators



      42.4




      43.3




      (0.9)




      (2.1)

      %

      Coolsculpting® Consumables



      76.3




      64.2




      12.1




      18.8

      %

      Skin Care



      14.6




      15.2




      (0.6)




      (3.9)

      %

      Botox® Therapeutics and Other



      603.0




      611.5




      (8.5)




      (1.4)

      %

      Botox® Therapeutics



      389.1




      390.4




      (1.3)




      (0.3)

      %

      Asacol®/Delzicol®



      36.1




      45.7




      (9.6)




      (21.0)

      %

      Constella®



      23.8




      24.1




      (0.3)




      (1.2)

      %

      Other Products



      154.0




      151.3




      2.7




      1.8

      %

      Other Revenues



      67.1




      65.3




      1.8




      2.8

      %

      Net revenues


      $

      3,402.0



      $

      3,504.7



      $

      (102.7)




      (2.9)

      %


















      Operating expenses:

















      Cost of sales(1)



      548.3




      537.1




      11.2




      2.1

      %

      Selling and marketing



      934.7




      928.7




      6.0




      0.6

      %

      General and administrative



      117.0




      141.7




      (24.7)




      (17.4)

      %

      Segment contribution


      $

      1,802.0



      $

      1,897.2



      $

      (95.2)




      (5.0)

      %

      Segment margin



      53.0

      %



      54.1

      %







      (1.1)

      %

      Segment gross margin(2)



      83.9

      %



      84.7

      %







      (0.8)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.









































      The following table details Allergan plc's non-GAAP product revenues for the three and twelve months ended December 31, 2019 and 2018.


      ALLERGAN PLC


      NON GAAP NET REVENUES TOP GLOBAL PRODUCTS


      (Unaudited; in millions)

      Table 12



      Three Months Ended December 31, 2019



      Three Months Ended December 31, 2018



      Movement



      US
      Specialized
      Therapeutics



      US

      General

       Medicine



      International



      Corporate



      Total



      US Specialized Therapeutics



      US

      General
      Medicine



      International



      Corporate



      Total



      Global Change



      Global Change Percentage


















































      Botox®

      $

      734.8



      $

      -



      $

      285.4



      $

      -




      1,020.2



      $

      691.4



      $

      -



      $

      254.5



      $

      -



      $

      945.9



      $

      74.3




      7.9

      %

      Juvederm® Collection


      166.4




      -




      180.9




      -




      347.3




      158.4




      -




      174.0




      -




      332.4




      14.9




      4.5

      %

      Linzess®/Constella®


      -




      231.2




      6.8




      -




      238.0




      -




      205.2




      6.4




      -




      211.6




      26.4




      12.5

      %

      Lumigan®/Ganfort®


      81.9




      -




      95.6




      -




      177.5




      74.0




      -




      96.9




      -




      170.9




      6.6




      3.9

      %

      Bystolic® /Byvalson®


      -




      169.6




      0.6




      -




      170.2




      -




      151.7




      0.4




      -




      152.1




      18.1




      11.9

      %

      Alphagan®/Combigan®


      94.5




      -




      43.1




      -




      137.6




      97.7




      -




      46.7




      -




      144.4




      (6.8)




      (4.7)

      %

      Eye Drops


      61.2




      -




      59.3




      -




      120.5




      47.9




      -




      71.7




      -




      119.6




      0.9




      0.8

      %

      Lo Loestrin®


      -




      156.2




      -




      -




      156.2




      -




      143.8




      -




      -




      143.8




      12.4




      8.6

      %

      Breast Implants


      67.1




      -




      15.1




      -




      82.2




      68.2




      -




      10.5




      -




      78.7




      3.5




      4.4

      %

      Viibryd®/Fetzima®


      -




      114.2




      3.6




      -




      117.8




      -




      95.5




      2.3




      -




      97.8




      20.0




      20.4

      %

      Alloderm®


      104.7




      -




      2.0




      -




      106.7




      94.9




      -




      2.5




      -




      97.4




      9.3




      9.5

      %

      Vraylar®


      -




      283.1




      -




      -




      283.1




      -




      150.5




      -




      -




      150.5




      132.6




      88.1

      %

      Coolsculpting® Consumables


      36.4




      -




      16.6




      -




      53.0




      54.5




      -




      23.4




      -




      77.9




      (24.9)




      (32.0)

      %

      Ozurdex ®


      31.6




      -




      66.7




      -




      98.3




      29.3




      -




      29.6




      -




      58.9




      39.4




      66.9

      %

      Carafate ® /Sulcrate ®


      -




      46.9




      0.9




      -




      47.8




      -




      54.1




      0.7




      -




      54.8




      (7.0)




      (12.8)

      %

      Zenpep®


      -




      80.8




      0.5




      -




      81.3




      -




      66.8




      0.4




      -




      67.2




      14.1




      21.0

      %

      Coolsculpting® Systems & Add On Applicators


      16.9




      -




      8.8




      -




      25.7




      26.8




      -




      21.5




      -




      48.3




      (22.6)




      (46.8)

      %

      Viberzi®


      -




      49.8




      0.4




      -




      50.2




      -




      48.9




      0.6




      -




      49.5




      0.7




      1.4

      %

      Namzaric®


      -




      20.2




      -




      -




      20.2




      -




      22.6




      -




      -




      22.6




      (2.4)




      (10.6)

      %

      Teflaro®


      -




      38.1




      3.7




      -




      41.8




      -




      30.0




      -




      -




      30.0




      11.8




      39.3

      %

      Dalvance®


      -




      26.4




      2.4




      -




      28.8




      -




      17.3




      1.0




      -




      18.3




      10.5




      57.4

      %

      Avycaz®


      -




      30.7




      -




      -




      30.7




      -




      24.6




      -




      -




      24.6




      6.1




      24.8

      %

      Kybella® /Belkyra®


      6.3




      -




      0.8




      -




      7.1




      7.2




      -




      1.0




      -




      8.2




      (1.1)




      (13.4)

      %

      Other Regenerative Medicine


      28.0




      -




      1.4




      -




      29.4




      29.8




      -




      1.4




      -




      31.2




      (1.8)




      (5.8)

      %

      Other Promoted Products


      1.7




      -




      (4.9)




      -




      (3.2)




      5.6




      -




      5.1




      -




      10.7




      (13.9)




      (129.9)

      %

      Total Promoted Brands & Brands with Ongoing Exclusivity


      1,431.5




      1,247.2




      789.7




      -




      3,468.4




      1,385.7




      1,011.0




      750.6




      -




      3,147.3




      321.1




      10.2

      %

      Restasis®


      309.0




      -




      18.7




      -




      327.7




      325.0




      -




      16.6




      -




      341.6




      (13.9)




      (4.1)

      %

      Asacol®/Delzicol®


      -




      8.5




      8.9




      -




      17.4




      -




      27.9




      10.7




      -




      38.6




      (21.2)




      (54.9)

      %

      Rapaflo®


      2.0




      -




      2.5




      -




      4.5




      18.9




      -




      1.8




      -




      20.7




      (16.2)




      (78.3)

      %

      Canasa®/Salofalk®


      -




      7.5




      4.7




      -




      12.2




      -




      38.8




      4.5




      -




      43.3




      (31.1)




      (71.8)

      %

      Saphris


      -




      36.3




      -




      -




      36.3




      -




      36.8




      -




      -




      36.8




      (0.5)




      (1.4)

      %

      Other LOE/ Risk


      -




      10.7




      -




      -




      10.7




      -




      28.3




      -




      -




      28.3




      (17.6)




      (62.2)

      %

      Total LOE/Risk


      311.0




      63.0




      34.8




      -




      408.8




      343.9




      131.8




      33.6




      -




      509.3




      (100.5)




      (19.7)

      %

      Aczone®


      2.5




      -




      -




      -




      2.5




      0.6




      -




      0.1




      -




      0.7




      1.8




      257.1

      %

      Other Divested


      10.5




      -




      0.1




      -




      10.6




      4.0



      5.2




      0.1




      -




      9.3




      1.3




      14.0

      %

      Total Divested


      13.0




      -




      0.1




      -




      13.1




      4.6




      5.2




      0.2




      -




      10.0




      3.1




      31.0

      %

      Total Brands facing LOE Risk/Divested


      324.0




      63.0




      34.9




      -




      421.9




      348.5




      137.0




      33.8




      -




      519.3




      (97.4)




      (18.8)

      %

      Skincare


      44.6




      -




      4.2




      -




      48.8




      40.4




      -




      3.6




      -




      44.0




      4.8




      10.9

      %

      Liletta®


      -




      22.5




      -




      -




      22.5




      -




      14.6




      -




      -




      14.6




      7.9




      54.1

      %

      Armour Thyroid


      -




      57.4




      -




      -




      57.4




      -




      53.4




      -




      -




      53.4




      4.0




      7.5

      %

      Savella®


      -




      21.5




      -




      -




      21.5




      -




      23.6




      -




      -




      23.6




      (2.1)




      (8.9)

      %

      Other Products Revenues


      21.1




      199.1




      88.9




      1.4




      310.5




      34.2




      158.3




      82.2




      2.8




      277.5




      33.0




      11.9

      %

      Total Other


      65.7




      300.5




      93.1




      1.4




      460.7




      74.6




      249.9




      85.8




      2.8




      413.1




      47.6




      11.5

      %

















































      Total Net Revenues

      $

      1,821.2



      $

      1,610.7



      $

      917.7



      $

      1.4




      4,351.0



      $

      1,808.8



      $

      1,397.9



      $

      870.2



      $

      2.8




      4,079.7



      $

      271.3




      6.6

      %




      Twelve Months Ended December 31, 2019



      Twelve Months Ended December 31, 2018



      Movement



      US

      Specialized

      Therapeutics



      US

      General

       Medicine



      International



      Corporate



      Global



      US

       Specialized

      Therapeutics



      US
      General

      Medicine



      International



      Corporate



      Global



      Global

      Change



      Global

      Change

       Percentage


















































      Botox®

      $

      2,730.5



      $

      -



      $

      1,060.8



      $

      -



      $

      3,791.3



      $

      2,545.8



      $

      -



      $

      1,031.6



      $

      -



      $

      3,577.4



      $

      213.9




      6.0

      %

      Juvederm® Collection


      587.5




      -




      656.1




      -




      1,243.6




      548.2




      -




      614.8




      -




      1,163.0




      80.6




      6.9

      %

      Linzess®/Constella®


      -




      803.2




      23.8




      -




      827.0




      -




      761.1




      24.1




      -




      785.2




      41.8




      5.3

      %

      Lumigan®/Ganfort®


      269.2




      -




      360.8




      -




      630.0




      291.8




      -




      392.6




      -




      684.4




      (54.4)




      (7.9)

      %

      Bystolic® /Byvalson®


      -




      600.6




      2.1




      -




      602.7




      -




      583.8




      2.0




      -




      585.8




      16.9




      2.9

      %

      Alphagan®/Combigan®


      360.0




      -




      162.0




      -




      522.0




      375.4




      -




      176.0




      -




      551.4




      (29.4)




      (5.3)

      %

      Eye Drops


      230.4




      -




      235.8




      -




      466.2




      202.7




      -




      279.7




      -




      482.4




      (16.2)




      (3.4)

      %

      Lo Loestrin®


      -




      588.9




      -




      -




      588.9




      -




      527.7




      -




      -




      527.7




      61.2




      11.6

      %

      Breast Implants


      254.4




      -




      0.6




      -




      255.0




      263.0




      -




      130.1




      -




      393.1




      (138.1)




      (35.1)

      %

      Viibryd®/Fetzima®


      -




      412.1




      11.4




      -




      423.5




      -




      342.4




      7.2




      -




      349.6




      73.9




      21.1

      %

      Alloderm®


      395.9




      -




      7.9




      -




      403.8




      407.3




      -




      8.0




      -




      415.3




      (11.5)




      (2.8)

      %

      Vraylar™


      -




      857.5




      -




      -




      857.5




      -




      487.1




      -




      -




      487.1




      370.4




      76.0

      %

      Coolsculpting® Consumables


      185.3




      -




      76.3




      -




      261.6




      235.3




      -




      64.2




      -




      299.5




      (37.9)




      (12.7)

      %

      Ozurdex ®


      125.5




      -




      274.6




      -




      400.1




      111.0




      -




      187.7




      -




      298.7




      101.4




      33.9

      %

      Carafate ® /Sulcrate ®


      -




      212.5




      3.0




      -




      215.5




      -




      217.8




      2.8




      -




      220.6




      (5.1)




      (2.3)

      %

      Zenpep®


      -




      288.0




      1.2




      -




      289.2




      -




      237.3




      0.4




      -




      237.7




      51.5




      21.7

      %

      Coolsculpting® Systems & Add On Applicators


      62.8




      -




      42.4




      -




      105.2




      126.3




      -




      43.3




      -




      169.6




      (64.4)




      (38.0)

      %

      Viberzi®


      -




      187.9




      1.6




      -




      189.5




      -




      176.5




      1.3




      -




      177.8




      11.7




      6.6

      %

      Namzaric®


      -




      88.6




      -




      -




      88.6




      -




      115.8




      -




      -




      115.8




      (27.2)




      (23.5)

      %

      Teflaro®


      -




      147.0




      6.0




      -




      153.0




      -




      128.0




      0.3




      -




      128.3




      24.7




      19.3

      %

      Dalvance®


      -




      81.9




      6.0




      -




      87.9




      -




      56.1




      2.3




      -




      58.4




      29.5




      50.5

      %

      Avycaz®


      -




      116.7




      -




      -




      116.7




      -




      94.6




      -




      -




      94.6




      22.1




      23.4

      %

      Kybella® /Belkyra®


      27.4




      -




      3.3




      -




      30.7




      31.8




      -




      6.3




      -




      38.1




      (7.4)




      (19.4)

      %

      Other Regenerative Medicines


      109.4




      -




      6.7




      -




      116.1




      116.6




      -




      8.8




      -




      125.4




      (9.3)




      (7.4)

      %

      Other Promoted and New Launch Products


      25.7




      -




      10.9




      -




      36.6




      21.5




      -




      20.5




      -




      42.0




      (5.4)




      (12.9)

      %

      Total Promoted Brands & Brands with Ongoing Exclusivity


      5,364.0




      4,384.9




      2,953.3




      -




      12,702.2




      5,276.7




      3,728.2




      3,004.0




      -




      12,008.9




      693.3




      5.8

      %

      Restasis®


      1,138.4




      -




      50.2




      -




      1,188.6




      1,197.0




      -




      64.5




      -




      1,261.5




      (72.9)




      (5.8)

      %

      Asacol®/Delzicol®


      -




      76.7




      36.1




      -




      112.8




      -




      130.8




      45.7




      -




      176.5




      (63.7)




      (36.1)

      %

      Rapaflo®


      23.5




      -




      6.0




      -




      29.5




      81.9




      -




      6.4




      -




      88.3




      (58.8)




      (66.6)

      %

      Canasa®/Salofalk®


      -




      31.5




      16.8




      -




      48.3




      -




      169.2




      17.6




      -




      186.8




      (138.5)




      (74.1)

      %

      Saphris


      -




      135.3




      -




      -




      135.3




      -




      139.7




      -




      -




      139.7




      (4.4)




      (3.1)

      %

      Other LOE/ Risk


      -




      72.1




      -




      -




      72.1




      -




      129.5




      -




      -




      129.5




      (57.4)




      (44.3)

      %

      Total LOE Risk


      1,161.9




      315.6




      109.1




      -




      1,586.6




      1,278.9




      569.2




      134.2




      -




      1,982.3




      (395.7)




      (20.0)

      %

      Aczone®


      9.3




      -




      -




      -




      9.3




      55.1




      -




      0.4




      -




      55.5




      (46.2)




      (83.2)

      %

      Other Divested


      34.0




      2.3




      0.6




      -




      36.9




      60.5



      19.9




      0.7




      -




      81.1




      (44.2)




      (54.5)

      %

      Total Divested


      43.3




      2.3




      0.6




      -




      46.2




      115.6




      19.9




      1.1




      -




      136.6




      (90.4)




      (66.2)

      %

      Total Brands facing LOE Risk


      1,205.2




      317.9




      109.7




      -




      1,632.8




      1,394.5




      589.1




      135.3




      -




      2,118.9




      (486.1)




      (22.9)

      %

      Skincare


      158.0




      -




      14.6




      -




      172.6




      138.8




      -




      15.2




      -




      154.0




      18.6




      12.1

      %

      Liletta®


      -




      79.1




      -




      -




      79.1




      -




      50.9




      -




      -




      50.9




      28.2




      55.4

      %

      Armour Thyroid


      -




      218.5




      -




      -




      218.5




      -




      198.8




      -




      -




      198.8




      19.7




      9.9

      %

      Savella®


      -




      88.5




      -




      -




      88.5




      -




      85.0




      -




      -




      85.0




      3.5




      4.1

      %

      Other Products Revenues


      92.8




      746.0




      324.4




      7.0




      1,170.2




      110.3




      670.9




      350.2




      14.5




      1,145.9




      24.3




      2.1

      %

      Total Other


      250.8




      1,132.1




      339.0




      7.0




      1,728.9




      249.1




      1,005.6




      365.4




      14.5




      1,634.6




      94.3




      5.8

      %

















































      Total Net Revenues

      $

      6,820.0



      $

      5,834.9



      $

      3,402.0



      $

      7.0




      16,063.9



      $

      6,920.3



      $

      5,322.9



      $

      3,504.7



      $

      14.5




      15,762.4



      $

      301.5




      1.9

      %

      SOURCE Allergan plc

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.